Table 1.

Contrast of NSCLC BM, breast cancer BM, melanoma BM and primary brain cancer (Glioblastoma).

	NSCLC BM	breast cancer BM	melanoma BM	Glioblastoma
Median number of tumors per patient	3 (1-6)	3 (1-11)	2 (1-6)	1
Median single tumor volume in cc	0.06	0.01	0.12	43.20
Preference of distribution	the infratentorial area, frontal lobe	structures supplied by the posterior circulation areas	supratentorial area	supratentorial area (frontal, temporal, parietal and occipital lobes)
Common Mutations	EGFR, ALK, KRAS, RET, ROS-1	HER2, PR, ER	BRAF, NRAS	EGFR, PTEN, TP53, CDKN2A
Median OS in Months	5.0 、16	10.0-15.0	2.5-6.0	11.4-15
Median age of the patients (year)	62	48.8	60	64
Common biomarker in ICI	PD-L1	PD-L1	PD-L1, CTLA-4	None

NSCLC, non-small cell lung cancer; BM, brain metastasis; OS, overall survival; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; KRAS, Kirsten rat sarcoma viral oncogene homolog; RET, rearranged during transfection; ROS-1, c-ros oncogene 1; HER2, Human epidermal growth factor receptor 2; PR, progesterone receptor; ER, estrogen receptor; BRAF, v-raf murine sarcoma viral oncogene homolog B1; NRAS, neuroblastoma RAS viral oncogene homolog; PTEN, phosphatase and tensin homolog; TP53, Tumor Protein P53; CDKN2A, Cyclin Dependent Kinase Inhibitor 2A.